Future therapies for the prevention and treatment of venous and arterial thrombosis

Expert Opinion on Investigational Drugs

Volumn 7, Issue 5, 1998, Pages 687-690

  McKean, M L ^a   Adelman, S J ^a  

^a PFIZER INC   (United States)

Author keywords

Anticoagulant; Antidote; Antithrombotic; Bleeding risk; Factor Ixa; Factor Xa; Glycoprotein IIb IIIa; Heparin; Low molecular weight heparin; Pharmacodynamics; Pharmacokinetics; Plasminogen activator inhibitor; Thrombin; Thrombin receptor; Thrombosis; Tissue factor Factor VIIa

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 9A; BLOOD CLOTTING FACTOR 9A INHIBITOR; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLASMINOGEN ACTIVATOR INHIBITOR; THROMBIN INHIBITOR; THROMBIN RECEPTOR; TISSUE FACTOR PATHWAY INHIBITOR; UNCLASSIFIED DRUG; WARFARIN;

ARTERY THROMBOSIS; BLOOD CLOT LYSIS; DRUG TARGETING; FUTUROLOGY; HUMAN; ORAL DRUG ADMINISTRATION; PROPHYLAXIS; SHORT SURVEY; VEIN THROMBOSIS;

EID: 0031942177     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.7.5.687     Document Type: Short Survey

References (0)